Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aetna’s Generic Gleevec Approach Combines Specialty Tiering, ‘Fail First’ Strategy

Executive Summary

Aetna oncology exec Kolodziej says the insurer expects the price discount for generic imatinib compared to the brand will be relatively modest at first.

You may also be interested in...



CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel